What does Attovia Therapeutics do?
Attovia Therapeutics is a clinical-stage biopharma company focused on developing treatments for immune-mediated diseases. It leverages its proprietary ATTOBODY biologics platform that uses spatial positioning technology to achieve biparatopic target engagement.
How much did they raise?
The company raised $90M in a Series C round, led by Deep Track Capital with participation from Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, and support from existing investors including Frazier Life Sciences and others.
What are their plans for the money?
The funds will be used to advance its lead assets, ATTO-1310 and ATTO-3712, potentially accelerating the development of innovative therapies for patients suffering from immune-mediated diseases.
What have they achieved so far?
Attovia Therapeutics has made significant progress with its proprietary ATTOBODY platform, establishing a promising pipeline of biotherapeutics for immune-mediated diseases.